Full Breakdown
Medicaid Rule Ends Federal Funding for Gender-Affirming Treatments in Minors
8/12/2026, 1:19:04 AM
Core Policy Change
The Centers for Medicare & Medicaid Services (CMS) announced that Medicaid and the Children’s Health Insurance Program (CHIP) will no longer cover cross-sex hormones, puberty blockers, or gender-affirming surgeries for patients under 18. The rule applies to new claims; existing recipients will retain coverage for six months after the rule takes effect. Mental-health services for gender dysphoria remain reimbursable under the programs.
Research Basis and Context
CMS cited the United Kingdom’s 2024 Cass Review, led by Dr. Hilary Cass, which identified “significant evidence gaps” and “serious safety concerns” regarding medical interventions for minors. The agency also referenced a broader review of national and international studies that found limited long-term safety data and a rapid pace of clinical adoption outpacing evidence of benefit. The decision follows a broader federal shift away from policies that expanded coverage for gender-affirming care in recent years.
Official Statements & Responses
Dr. Mehmet Oz, CMS Administrator, said the rule aligns with the administration’s goal of protecting children from “experimental and life-altering procedures” that lack reliable evidence of clinical benefit. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.
Implementation Details
The rule will be phased in, allowing a six-month window for current patients to complete treatment courses funded by Medicaid or CHIP. After that period, any new requests for cross-sex hormones, puberty blockers, or gender-affirming surgeries for minors will be denied. Providers must adjust billing practices accordingly, and states administering CHIP will follow the federal guidance.
Verbatim Quotes
- “Today, we are ending federal taxpayer funding for sex-rejecting procedures on children,” — Secretary Kennedy, under secretary
